This is a prospective, cluster-randomized, two-arm, comparative study aimed at determining whether addition of tizanidine ( an oral muscle relaxant) to a multimodal pain regimen following primary TKA reduces opioid consumption.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
240
Tizanidine 2 mg q8h (standing; # 42 tablets) + Multimodal pain regimen
Rothman Orthopaedic Institute
Philadelphia, Pennsylvania, United States
opioid consumption (MME) postoperatively
Primary outcome is patients total opioid consumption for the first 14 days after surgery.
Time frame: the first 14-days postoperatively
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.